Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean I Tracy

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Frontiers in Immunology|September 1, 2023
Cytotoxic CD4 T cells in the mucosa and in cancerHrishi Venkatesh, Sean I Tracy, Michael A Farrar
BMJ Case Reports|May 22, 2016
Rare case of simultaneous enterococcal endocarditis and prosthetic joint infectionSean I Tracy, Sherry-Ann Brown, John T Ratelle, et al.
Frontiers in Cell and Developmental Biology|October 11, 2021
Phenotypic and Functional Diversity in Regulatory T CellsLouisa E Sjaastad, David L Owen, Sean I Tracy, et al.
Current Opinion in Virology|May 21, 2013
The pathogenesis of Epstein-Barr virus persistent infectionDavid A Thorley-Lawson, Jared B Hawkins, Sean I Tracy, et al.
Journal of Virology|September 7, 2012
Persistence of Epstein-Barr virus in self-reactive memory B cellsSean I Tracy, Kristina Kakalacheva, Jan D Lünemann, et al.
Blood|March 11, 2022
Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemiaSean I Tracy, Hrishi Venkatesh, Can Hekim, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSEElizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centenos, et al.
Blood|September 4, 2025
Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cellsHrishi Venkatesh, Enoc Granados Centeno, Qianyun Luo, et al.
Cancers|August 29, 2024
Patients with <i>TP53</i>-Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective StudyNuttavut Sumransub, Gabriel K Steinwand, Keith Cordner, et al.
American Journal of Hematology|March 28, 2019
The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomasSean I Tracy, Melissa C Larson, Andrew L Feldman, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Frontiers in Immunology|September 1, 2023
Cytotoxic CD4 T cells in the mucosa and in cancerHrishi Venkatesh, Sean I Tracy, Michael A Farrar
BMJ Case Reports|May 22, 2016
Rare case of simultaneous enterococcal endocarditis and prosthetic joint infectionSean I Tracy, Sherry-Ann Brown, John T Ratelle, et al.
Frontiers in Cell and Developmental Biology|October 11, 2021
Phenotypic and Functional Diversity in Regulatory T CellsLouisa E Sjaastad, David L Owen, Sean I Tracy, et al.
Current Opinion in Virology|May 21, 2013
The pathogenesis of Epstein-Barr virus persistent infectionDavid A Thorley-Lawson, Jared B Hawkins, Sean I Tracy, et al.
Journal of Virology|September 7, 2012
Persistence of Epstein-Barr virus in self-reactive memory B cellsSean I Tracy, Kristina Kakalacheva, Jan D Lünemann, et al.
Blood|March 11, 2022
Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemiaSean I Tracy, Hrishi Venkatesh, Can Hekim, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSEElizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centenos, et al.
Blood|September 4, 2025
Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cellsHrishi Venkatesh, Enoc Granados Centeno, Qianyun Luo, et al.
Cancers|August 29, 2024
Patients with <i>TP53</i>-Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective StudyNuttavut Sumransub, Gabriel K Steinwand, Keith Cordner, et al.
American Journal of Hematology|March 28, 2019
The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomasSean I Tracy, Melissa C Larson, Andrew L Feldman, et al.
Pageof 2